<code id='6BBB7C2534'></code><style id='6BBB7C2534'></style>
    • <acronym id='6BBB7C2534'></acronym>
      <center id='6BBB7C2534'><center id='6BBB7C2534'><tfoot id='6BBB7C2534'></tfoot></center><abbr id='6BBB7C2534'><dir id='6BBB7C2534'><tfoot id='6BBB7C2534'></tfoot><noframes id='6BBB7C2534'>

    • <optgroup id='6BBB7C2534'><strike id='6BBB7C2534'><sup id='6BBB7C2534'></sup></strike><code id='6BBB7C2534'></code></optgroup>
        1. <b id='6BBB7C2534'><label id='6BBB7C2534'><select id='6BBB7C2534'><dt id='6BBB7C2534'><span id='6BBB7C2534'></span></dt></select></label></b><u id='6BBB7C2534'></u>
          <i id='6BBB7C2534'><strike id='6BBB7C2534'><tt id='6BBB7C2534'><pre id='6BBB7C2534'></pre></tt></strike></i>

          
          WSS

          Axovant Sciences(AXON) is the main event in biotech’s September cavalcade of clinical trial readouts, but while we wait, it’s a good idea to prep for important — and stock-moving — data releases from Zogenix(ZGNX) and Amicus Therapeutics(FOLD).

          Zogenix’s lead drug, called ZX008, is a low-dose liquid formulation of the old serotonin booster fenfluramine. The company is developing ZX008 to treat children with Dravet syndrome, a rare and severe type of epilepsy.

          advertisement

          You might remember fenfluramine as part of the “fen-phen” obesity regimen that was pulled from the market in 1997 because fenfluramine (at a higher dose) caused severe damage to people’s heart valves.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          entertainment